Human Papillomavirus (HPV) L1 Serum Antibodies and the Risk of Subsequent Oral HPV Acquisition in Men: The HIM Study

J Infect Dis. 2016 Jul 1;214(1):45-8. doi: 10.1093/infdis/jiw083. Epub 2016 Feb 29.

Abstract

The role of antibody-mediated immunity in preventing newly acquired oral human papillomavirus (HPV) is not well understood. Among 1618 men participating in the HPV Infection in Men (HIM) Study, we evaluated oral rinses for HPV DNA and baseline sera for HPV-6, -11, -16, and -18 L1 antibodies. Thirty percent of men (486) were seropositive for ≥1 HPV type, and 25 men developed incident oral HPV infection (HPV-6 was detected in 7, HPV-11 in 0, HPV-16 in 17, and HPV-18 in 1). Cox models revealed that men with circulating antibodies to HPV-6, -11, -16, or -18 were not less likely to acquire type-specific oral HPV than men without antibodies (hazard ratio for the risk of acquiring HPV-6, -11, -16, or -18, 1.63; 95% confidence interval, .56-4.76).

Keywords: HPV16; antibodies; men; oral HPV; serology.

Publication types

  • Research Support, N.I.H., Intramural
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Viral / blood*
  • Antibodies, Viral / immunology*
  • Brazil
  • Humans
  • Male
  • Mexico
  • Middle Aged
  • Oropharyngeal Neoplasms / etiology*
  • Oropharyngeal Neoplasms / immunology*
  • Papillomaviridae / immunology*
  • Papillomavirus Infections / complications*
  • Papillomavirus Infections / transmission*
  • Proportional Hazards Models
  • Prospective Studies
  • Risk Assessment
  • United States
  • Young Adult

Substances

  • Antibodies, Viral